Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 2: 143 - 151

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.02.002

Basic research

Quantitative characteristics of serum lipoprotein phenotypes for HBV patients

  • Xiaoxuan YI ,
  • Senlin HU ,
  • Yang SUN ,
  • Qingxia HUANG ,
  • Huiru TANG
Expand
  • 1.School of Life Sciences, Human Phenome Institute, State Key Laboratory of Genetic Engineering, Metabonomics and Systems Biology Laboratory at Shanghai International Centre for Molecular Phenomics, Shanghai 200438, China
    2.Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
    3.Zhongshan Hospital, Fudan University, Shanghai 200032, China
TANG Huiru, E-mail: huiru_tang@fudan.edu.cn.
HUANG Qingxia, E-mail: qingxhuang@fudan.edu.cn

Received date: 2022-12-08

  Accepted date: 2023-02-03

  Online published: 2023-02-28

Supported by

National Key R&D Program of China(2021YFC2500600);National Natural Science Foundation of China(31821002)

Fold

Abstract

Objective ·Previous studies showed that hepatitis B virus (HBV) infection caused outstanding changes in host lipoproteins. However, there are no reports on such component changes of lipoprotein subfractions. This study aimed to quantify the HBV-caused changes in the serum lipoprotein subfractions and their components. Methods ·Hepatitis B surface antigen-positive [HBsAg (+)] patients at Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from March to June 2017 were included (n=40), and 40 HBsAg-negative [HBsAg (-)] population were matched as controls. Serum lipoprotein subfractions and their components were quantified by using 1H-NMR. Orthogonal partial least-squares discriminant analysis (OPLS-DA), variance analysis between the two groups, logistic regression analysis and Spearman correlation analysis were conducted to reveal the lipoprotein changes in chronic HBV patients against controls. Results ·HBsAg (+) population had significantly lower levels in most lipoprotein subfractions than HBsAg (-) population. After adjustments for age, gender, hypertension, diabetes mellitus and coronary heart disease, the levels of total VLDL, VLDL1-VLDL3, IDL, HDL4, non-HDL and their components were protective factors for HBV infection (OR < 1, P < 0.01). In contrast, VLDL5-(TAG/LP) was a risk factor for HBV infection (OR > 1, P < 0.01). In addition, the severity of inflammation in the HBsAg (+) population was negatively correlated with the levels of lipids in HDL4 with correlation coefficient ranging from -0.71 to -0.51(P≤ 0.002). Six lipoprotein subfractions were obtained through feature screening, and the AUC of HBV infection diagnosis model was 0.861. Conclusion ·HBV infection causes significant changes in liver-excretion of lipoproteins and their circulation metabolism; the lipoprotein phenotypes can differentiate HBV-infected patients from controls.

Key words： lipoprotein; 1H-NMR; hepatitis B virus; chronic hepatitis B

Cite this article

Xiaoxuan YI , Senlin HU , Yang SUN , Qingxia HUANG , Huiru TANG . Quantitative characteristics of serum lipoprotein phenotypes for HBV patients[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(2) : 143 -151 . DOI: 10.3969/j.issn.1674-8115.2023.02.002

References

1 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华肝脏病杂志, 2019, 27(12): 938-961.
1 Chinese Society of Infectious Diseases Chinese Medical Association, Chinese Society of Hepatology Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version)[J]. Chinese Journal of Hepatology, 2019, 27(12): 938-961.
2 MCGLYNN K A, PETRICK J L, EL-SERAG H B. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2021, 73(S1): 4-13.
3 LIU Z Q, JIANG Y F, YUAN H B, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention[J]. J Hepatol, 2019, 70(4): 674-683.
4 NGUYEN M H, WONG G, GANE E, et al. Hepatitis B virus: Advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev, 2020, 33(2): e0046-e0019.
5 BAR-YISHAY I, SHAUL Y, SHLOMAI A. Hepatocyte metabolic signalling pathways and regulation of hepatitis B virus expression[J]. Liver Int, 2011, 31(3): 282-290.
6 HUANG Q X, LEI H H, DING L F, et al. Stimulated phospholipid synthesis is key for hepatitis B virus replications[J]. Sci Rep, 2019, 9(1): 12989.
7 JOO E J, CHANG Y, YEOM J S, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study[J]. Hepatology, 2017, 65(3): 828-835.
8 WANG F B, ZHU C L, LIU X H, et al. HBV inhibits apoB production via the suppression of MTP expression[J]. Lipids Health Dis, 2011, 10: 207.
9 ZHU C L, GAO G S, SONG H, et al. Hepatitis B virus inhibits apolipoprotein A5 expression through its core gene[J]. Lipids Health Dis, 2016, 15(1): 178.
10 ZHU C L, ZHU H C, SONG H, et al. Hepatitis B virus inhibits the in vivo and in vitro synthesis and secretion of apolipoprotein C3[J]. Lipids Health Dis, 2017, 16(1): 213.
11 HSU C S, LIU C H, WANG C C, et al. Impact of hepatitis B virus infection on metabolic profiles and modifying factors[J]. J Viral Hepat, 2012, 19(2): E48-E57.
12 JAN C F, CHEN C J, CHIU Y H, et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening Study No. 10)[J]. Int J Obes (Lond), 2006, 30(5): 794-799.
13 QUAYE O, AMUZU B G, ADADEY S M, et al. Effect of hepatitis B virus (HBV) infection on lipid profile in Ghanaian patients[J]. Virology (Auckl), 2019, 10: 1178122X19827606.
14 TARGHER G, BERTOLINI L, PADOVANI R, et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C[J]. J Hepatol, 2007, 46(6): 1126-1132.
15 ZUO D, AN H H, LI J H, et al. The application value of lipoprotein particle numbers in the diagnosis of HBV-related hepatocellular carcinoma with BCLC stage 0-A[J]. J Pers Med, 2021, 11(11): 1143.
16 KULKARNI K R. Cholesterol profile measurement by vertical auto profile method[J]. Clin Lab Med, 2006, 26(4): 787-802.
17 RáDIKOVá ?, PENESOVá A, VL?EK M, et al. Lipoprotein profiling in early multiple sclerosis patients: effect of chronic inflammation?[J]. Lipids Health Dis, 2020, 19(1): 49.
18 KAUFMAN S L. Analysis of biomolecules using electrospray and nanoparticle methods: the gas-phase electrophoretic mobility molecular analyzer (GEMMA)[J]. J Aerosol Sci, 1998, 29(5/6): 537-552.
19 CLOUET-FORAISON N, GAIE-LEVREL F, GILLERY P, et al. Advanced lipoprotein testing for cardiovascular diseases risk assessment: a review of the novel approaches in lipoprotein profiling[J]. Clin Chem Lab Med, 2017, 55(10): 1453-1464.
20 JIMéNEZ B, HOLMES E, HEUDE C, et al. Quantitative lipoprotein subclass and low molecular weight metabolite analysis in human serum and plasma by 1H NMR spectroscopy in a multilaboratory trial [J]. Anal Chem, 2018, 90(20): 11962-11971.
21 YASUMOTO J, KASAI H, YOSHIMURA K, et al. Hepatitis B virus prevents excessive viral production via reduction of cell death-inducing DFF45-like effectors [J]. J Gen Virol, 2017, 98(7): 1762-1773.
22 ZHANG J X, LING N, LEI Y, et al. Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: A potential target of antiviral therapy for chronic hepatitis B [J]. Front Microbiol, 2021, 12: 636897.
23 ARAIN S Q, TALPUR F N, CHANNA N A, et al. Serum lipids as an indicator for the alteration of liver function in patients with hepatitis B[J]. Lipids Health Dis, 2018, 17(1): 36.
24 OEHLER N, VOLZ T, BHADRA O D, et al. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism[J]. Hepatology, 2014, 60(5): 1483-1493.
25 KONTUSH A, CHANTEPIE S, CHAPMAN M J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress[J]. Arterioscler Thromb Vasc Biol, 2003, 23(10): 1881-1888.
26 HAN Y H, ONUFER E J, HUANG L H, et al. Enterically derived high-density lipoprotein restrains liver injury through the portal vein[J]. Science, 2021, 373(6553): eabe6729.
Options
Outlines

/

〈 〉